| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
B
Stephen Rice,3 and
Steven L. Bachenheimer1,2*
Department of Microbiology and Immunology,1 Lineberger Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599-7290,2 Department of Microbiology, University of Minnesota Medical School, 420 Delaware Street SE, Mayo Mail Code 196, Minneapolis, Minnesota 554553
Received 31 May 2006/ Accepted 11 August 2006
The ability of herpes simplex virus type 1 (HSV-1) to activate NF-
B has been well documented. Beginning at 3 to 5 h postinfection, HSV-1 induces a robust and persistent nuclear translocation of an NF-
B-dependent (p50/p65 heterodimer) DNA binding activity, as measured by electrophoretic mobility shift assay. Activation requires virus binding and entry, as well as de novo infected-cell protein synthesis, and is accompanied by loss of both I
B
and I
Bß. In this study, we identified loss of I
B
as a marker of NF-
B activation, and infection with mutants with individual immediate-early (IE) regulatory proteins deleted indicated that ICP27 was necessary for I
B
loss. Analysis of both N-terminal and C-terminal mutants of ICP27 identified the region from amino acids 21 to 63 as being necessary for I
B
loss. Additional experiments with mutant viruses with combinations of IE genes deleted revealed that the ICP27-dependent mechanism of NF-
B activation may be augmented by functional ICP4. We also analyzed two additional markers for NF-
B activation, phosphorylation of the p65 subunit on Ser276 and Ser536. Phosphorylation of both serines was induced upon HSV infection and required functional ICP4 and ICP27. Pharmacological inhibitor studies revealed that both I
B
and Ser276 phosphorylation were dependent on Jun N-terminal protein kinase activity, while Ser536 phosphorylation was not affected during inhibitor treatment. These results demonstrate that there are several layers of regulation of NF-
B activation during HSV infection, highlighting the important role that NF-
B may play in infection.
Published ahead of print on 23 August 2006.
Present address: Lewis Thomas Lab, Department of Molecular Biology, Princeton University, Washington Rd., Princeton, NJ 08544-1014.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|